Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 26, 2022; 10(12): 3698-3708
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3698
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3698
Table 2 The association between the expression of SRY-related HMG box-2 and clinicopathology of patients with triple-negative breast cancer, n (%)
Clinical data | Cases | SOX2 positive expression rate | χ2 | P value |
Age (yr) | 0.000 | 0.994 | ||
< 50 | 55 | 41 (74.55) | ||
≥ 50 | 63 | 47 (74.60) | ||
BMI (kg/m2) | 0.545 | 0.460 | ||
< 22 | 60 | 43 (71.67) | ||
≥ 22 | 58 | 45 (77.59) | ||
Karnofsky score (points) | 0.574 | 0.449 | ||
< 70 | 52 | 37 (71.15) | ||
≥ 70 | 66 | 51 (77.27) | ||
Differentiation degree | 0.000 | 0.988 | ||
High differentiation | 51 | 38 (74.51) | ||
Medium low differentiation | 67 | 50 (74.63) | ||
Intravascular tumor thrombus | 7.689 | 0.006 | ||
Yes | 25 | 24 (96.00) | ||
No | 93 | 64 (68.82) | ||
Tumor size | 0.420 | 0.517 | ||
> 5 cm | 53 | 38 (71.70) | ||
≤ 5 cm | 65 | 50 (76.92) | ||
TNM stages | 7.180 | 0.007 | ||
III | 94 | 65 (69.15) | ||
IV | 24 | 23 (95.83) | ||
Pathological type | 0.049 | 0.825 | ||
Invasive ductal carcinoma | 96 | 72 (75.00) | ||
Other | 22 | 16 (72.73) | ||
Ki-67 | 0.073 | 0.787 | ||
≤ 14% | 37 | 27 (72.97) | ||
> 14% | 81 | 61 (75.31) | ||
P53 | 0.741 | 0.389 | ||
Positive | 79 | 57 (72.15) | ||
Negative | 39 | 31 (79.49) |
- Citation: Ding F, Chen RY, Hou J, Guo J, Dong TY. Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer. World J Clin Cases 2022; 10(12): 3698-3708
- URL: https://www.wjgnet.com/2307-8960/full/v10/i12/3698.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i12.3698